Sort
10,766 grants matching “checkpoint inhibitor”
Studies of DNA damage checkpoints
$418,239Paul R Russell · Scripps Research Institute, The · R01 · FY2007 · CA
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface
$418,234Melody A Swartz · University Of Chicago · R01 · FY2024 · CA
Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS)
$418,197Carmen R Mikacenic · Benaroya Research Inst At Virginia Mason · R01 · FY2024 · HL
Project 3: The ATM Kinase as a Therapeutic Target in Drug Resistant NSCLC with Brain Metastasis
$418,152Don X Nguyen · Yale University · P50 · FY2025 · CA
Small Molecule Activators of Procaspases as Anti-Cancer Agents
$417,934Paul Hergenrother · University Of Illinois At Urbana-Champaign · R01 · FY2018 · CA
Cell surface receptor targeted therapies for brain tumors
$417,858Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2025 · CA
Evaluation of Immune-based Combinations in Prostate Cancer
$417,740Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Nanocage-based systemic delivery of TGFb trap for immunomodulation of brain neoplasms
$417,726Jung Soo Suk · University Of Maryland Baltimore · R01 · FY2025 · NS
Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells
$417,650James Jackson · Tulane University Of Louisiana · R01 · FY2025 · CA
INTERACITONS OF HPV ONCOGENES WITH THE P53 PATHWAY
$417,514Fred Hutchinson Cancer Research Center · R01 · FY2001 · CA
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
$417,500Aaron N Hata · Massachusetts General Hospital · R01 · FY2023 · CA
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
$417,500Aaron N Hata · Massachusetts General Hospital · R01 · FY2025 · CA
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING
$417,319Poulikos I Poulikakos · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · CA
Role of microbial-modulated bile acid receptor signaling in breast cancer
$417,301Liza Makowski Hayes · University Of Tennessee Health Sci Ctr · R01 · FY2020 · CA
Replication Associated Genetic Rearrangements
$417,145Brandeis University · R01 · FY2003 · GM
Project 1: Glutaminolytic GDH1 activation-dependent immunotherapy resistance in LKB1-mutant lung adenocarcinoma
$416,967Sumin Kang · Emory University · P01 · FY2023 · CA
Metabolic interactions between tumor cells and the immunce system in GBM A potential Achilles heel of GBM for novel therapeutics
$416,964Loic Pierre Deleyrolle · University Of Florida · R01 · FY2023 · NS
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma
$416,787Cassian Yee · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma
$416,783Cassian Yee · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA
Deciphering MDSC function for GBM targeting
$416,765Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R01 · FY2019 · NS
Genetic Mechanisms Controlling Kidney Cancer Immune Escape
$416,677Haydn Kissick · Emory University · R01 · FY2025 · CA
Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment
$416,647E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2020 · NS
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
$416,290Weidong Xu · Endeavor Health Clinical Operations · R01 · FY2025 · CA
Double-Strand Break Sensing, Signaling, and Repair
$416,261John A Tainer · University Of Calif-Lawrenc Berkeley Lab · P01 · FY2012 · CA
Tumor Suppressor Qualities and Mechanisms of LZAP Activity
$416,250Wendell G Yarbrough · Yale University · R01 · FY2016 · DE